首页 > 最新文献

Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders最新文献

英文 中文
Expert Opinion on the Extensive Use of Prescription Crystalline Glucosamine Sulfate in the Multimodal Treatment of Osteoarthritis in Ukraine, Kazakhstan, Uzbekistan, and Armenia. 关于在乌克兰、哈萨克斯坦、乌兹别克斯坦和亚美尼亚广泛使用处方结晶硫酸葡萄糖胺治疗骨关节炎的专家意见。
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2020-08-04 eCollection Date: 2020-01-01 DOI: 10.1177/1179544120946743
Andriy M Gnylorybov, Semen K Ter-Vartanian, Irina Y Golovach, Oleg E Vyrva, Oleksandr A Burianov, Gulnara S Yesirkepova, Murodjon E Irismetov, Mashkhura Z Rizamuhamedova, Valentina S Vardanyan, Knarik V Ginosyan

Objective: The present work was led by a multidisciplinary panel of experts and proposes an extensive review on the use of prescription crystalline glucosamine sulfate (pCGS) in the multimodal treatment of osteoarthritis (OA) applicable in Ukraine and other Commonwealth of Independent States (CIS) countries.

Methods: A panel of rheumatologists, orthopedic surgeons, and field experts from Ukraine and CIS regions discussed the management of OA. Literature was systematically searched using Medline, EMBASE, CIHNAL, and Cochrane Library databases. The 2-day meeting critically reviewed the available literature, treatment algorithms, pharmacoeconomic aspects, and real-world instances to form a multimodal approach based both on real-life clinical practice and systematic literature research for the management of OA in Ukraine and CIS countries.

Expert opinion: pCGS plays a pivotal role in the stepwise approach to OA treatment. If it is necessary (step 1), the combined use of pCGS with paracetamol and topical nonsteroidal anti-inflammatory drugs (NSAIDs) has been recommended. If symptoms persist, oral NSAIDs and intra-articular (IA) hyaluronic acid or corticosteroids are added to the therapy (step 2) of pCGS in the patients. In case of insufficient relief and severe OA (step 3), pCGS along with oral NSAIDs, IA corticosteroids, and duloxetine have been recommended. Patient stratification with regular monitoring and careful alterations in treatment were advocated.

Conclusions: This expert opinion article recommends a modified approach to the existing guidelines incorporating pCGS in treatment modality of OA in Ukraine and CIS countries. Extensive use of pCGS targets early symptomatic relief in OA while limiting the adverse effects due to long-term use of analgesics and NSAIDs.

目的:目前的工作是由一个多学科专家小组领导,并提出了一个广泛的审查使用处方结晶硫酸氨基葡萄糖(pCGS)在多模式治疗骨关节炎(OA)适用于乌克兰和其他独立国家联合体(CIS)国家。方法:一组来自乌克兰和独联体地区的风湿病学家、骨科医生和现场专家讨论了OA的管理。文献系统检索使用Medline, EMBASE, CIHNAL和Cochrane图书馆数据库。为期两天的会议严格审查了现有文献、治疗算法、药物经济学方面和现实世界的实例,形成了一种基于现实临床实践和系统文献研究的多模式方法,用于乌克兰和独联体国家OA管理。专家意见:pCGS在渐进式OA治疗中起着关键作用。如果有必要(步骤1),建议将pCGS与扑热息痛和局部非甾体抗炎药(NSAIDs)联合使用。如果症状持续,口服非甾体抗炎药和关节内(IA)透明质酸或皮质类固醇加入到患者的pCGS治疗(第2步)中。在缓解不足和严重OA(步骤3)的情况下,建议pCGS与口服非甾体抗炎药、IA皮质类固醇和度洛西汀一起使用。提倡患者分层,定期监测和仔细改变治疗。结论:这篇专家意见文章建议对乌克兰和独联体国家OA治疗方式中纳入pCGS的现有指南进行修改。广泛使用pCGS的目标是早期症状缓解OA,同时限制长期使用镇痛药和非甾体抗炎药的不良反应。
{"title":"Expert Opinion on the Extensive Use of Prescription Crystalline Glucosamine Sulfate in the Multimodal Treatment of Osteoarthritis in Ukraine, Kazakhstan, Uzbekistan, and Armenia.","authors":"Andriy M Gnylorybov,&nbsp;Semen K Ter-Vartanian,&nbsp;Irina Y Golovach,&nbsp;Oleg E Vyrva,&nbsp;Oleksandr A Burianov,&nbsp;Gulnara S Yesirkepova,&nbsp;Murodjon E Irismetov,&nbsp;Mashkhura Z Rizamuhamedova,&nbsp;Valentina S Vardanyan,&nbsp;Knarik V Ginosyan","doi":"10.1177/1179544120946743","DOIUrl":"https://doi.org/10.1177/1179544120946743","url":null,"abstract":"<p><strong>Objective: </strong>The present work was led by a multidisciplinary panel of experts and proposes an extensive review on the use of prescription crystalline glucosamine sulfate (pCGS) in the multimodal treatment of osteoarthritis (OA) applicable in Ukraine and other Commonwealth of Independent States (CIS) countries.</p><p><strong>Methods: </strong>A panel of rheumatologists, orthopedic surgeons, and field experts from Ukraine and CIS regions discussed the management of OA. Literature was systematically searched using Medline, EMBASE, CIHNAL, and Cochrane Library databases. The 2-day meeting critically reviewed the available literature, treatment algorithms, pharmacoeconomic aspects, and real-world instances to form a multimodal approach based both on real-life clinical practice and systematic literature research for the management of OA in Ukraine and CIS countries.</p><p><strong>Expert opinion: </strong>pCGS plays a pivotal role in the stepwise approach to OA treatment. If it is necessary (step 1), the combined use of pCGS with paracetamol and topical nonsteroidal anti-inflammatory drugs (NSAIDs) has been recommended. If symptoms persist, oral NSAIDs and intra-articular (IA) hyaluronic acid or corticosteroids are added to the therapy (step 2) of pCGS in the patients. In case of insufficient relief and severe OA (step 3), pCGS along with oral NSAIDs, IA corticosteroids, and duloxetine have been recommended. Patient stratification with regular monitoring and careful alterations in treatment were advocated.</p><p><strong>Conclusions: </strong>This expert opinion article recommends a modified approach to the existing guidelines incorporating pCGS in treatment modality of OA in Ukraine and CIS countries. Extensive use of pCGS targets early symptomatic relief in OA while limiting the adverse effects due to long-term use of analgesics and NSAIDs.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"13 ","pages":"1179544120946743"},"PeriodicalIF":2.6,"publicationDate":"2020-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179544120946743","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38283492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The Differences in Imaging Findings Between Painless and Painful Osteoarthritis of the Hip. 无痛性和疼痛性髋关节骨关节炎影像学表现的差异。
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2020-08-04 eCollection Date: 2020-01-01 DOI: 10.1177/1179544120946747
Hiroaki Kijima, Shin Yamada, Natsuo Konishi, Hitoshi Kubota, Hiroshi Tazawa, Takayuki Tani, Norio Suzuki, Keiji Kamo, Yoshihiko Okudera, Masashi Fujii, Ken Sasaki, Tetsuya Kawano, Yosuke Iwamoto, Itsuki Nagahata, Takanori Miura, Naohisa Miyakoshi, Yoichi Shimada

Purpose: In osteoarthritis of the hip, the pain may be strong even if the deformity is mild, but the pain may be mild even if the deformity is severe. If the factors related to the pain can be identified on imaging, reducing such factors can alleviate the pain, and effective measures can be taken for cases where surgery cannot be performed. In addition, imaging findings related to the pain are also important information for determining the procedures and the timing of surgery. Thus, the purpose of this study was to identify the differences in features of osteoarthritis seen on imaging between painless and painful osteoarthritis of the hip.

Methods: The subjects were the patients with hip osteoarthritis who visited our department in 2015 and who underwent x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), a total of 29 patients (54 hip joints; mean age 63 years; 8 males and 21 females). The degree of osteoarthritis was determined using the Tönnis grade from the x-ray image. The cartilage morphology, intensity changes of bone marrow on MRI (subchondral bone marrow lesions [BMLs]), osteophytes, joint effusions, and paralabral cysts were scored based on the Hip Osteoarthritis MRI Scoring System (HOAMS). The cross-sectional area of the psoas major muscle at the level of the iliac crest was measured on CT, and the psoas index (PI; the cross-sectional area ratio of the psoas major muscle to the lumbar 4/5 intervertebral disc) was calculated to correct for the difference in physique. Then, the relationships between these and visual analog scale (VAS) scores of pains were evaluated.

Results: The average VAS was 55.4 ± 39 mm. The PI and all items of HOAMS correlated with the VAS. The average VAS of Tönnis grade 3 osteoarthritis was 75.8 ± 26 mm. When investigating only Tönnis grade 3 osteoarthritis, the differences between cases with less than average pain and those with above average pain were the BML score in the central-inferior femoral head (P = .0213), the osteophyte score of the inferomedial femoral head (P = .0325), and the PI (P = .0292).

Conclusion: Investigation of the differences between painless and painful osteoarthritis of the hip showed that the cases with more pain have BMLs of the femoral head on MRI that extend not only to the loading area, but also to the central-inferior area. Even with the same x-ray findings, the pain was stronger in patients with severe psoas atrophy. Thus, the instability due to muscle atrophy may also play a role in the pain of hip osteoarthritis.

目的:髋关节骨关节炎,即使畸形轻微,疼痛也可能很强烈,但即使畸形严重,疼痛也可能很轻微。如果能在影像学上识别出与疼痛相关的因素,减少这些因素可以减轻疼痛,对于不能手术的病例,可以采取有效的措施。此外,与疼痛相关的影像学表现也是确定手术程序和手术时机的重要信息。因此,本研究的目的是确定髋关节无痛性骨关节炎和疼痛性骨关节炎在影像学上的特征差异。方法:研究对象为2015年来我科就诊并行x线、CT、MRI检查的髋关节骨性关节炎患者,共29例(54个髋关节;平均年龄63岁;男性8人,女性21人)。骨性关节炎的程度通过x线图像的Tönnis分级来确定。根据髋关节骨关节炎MRI评分系统(HOAMS)对软骨形态、MRI上骨髓强度变化(软骨下骨髓病变[BMLs])、骨赘、关节积液和肱旁囊肿进行评分。在CT上测量髂嵴水平腰肌横截面积,腰大肌指数(PI;计算腰大肌与腰椎间盘(4/5)的横截面积比,以纠正体格上的差异。然后,评估这些与视觉模拟评分(VAS)之间的关系。结果:VAS平均为55.4±39 mm。PI和HOAMS各项目均与VAS相关。Tönnis 3级骨关节炎VAS平均值为75.8±26 mm。当仅调查Tönnis 3级骨关节炎时,疼痛低于平均水平的患者与疼痛高于平均水平的患者之间的差异是股骨头中下段BML评分(P = 0.0213),股骨头内侧段骨癣评分(P = 0.0325)和PI (P = 0.0292)。结论:通过对无痛性和疼痛性髋关节骨性关节炎差异的研究发现,疼痛较多的患者MRI上股骨头的脑损伤不仅延伸到负荷区,而且延伸到中下区。即使x线检查结果相同,严重腰肌萎缩患者的疼痛也更强烈。因此,肌肉萎缩引起的不稳定也可能在髋关节骨关节炎的疼痛中起作用。
{"title":"The Differences in Imaging Findings Between Painless and Painful Osteoarthritis of the Hip.","authors":"Hiroaki Kijima,&nbsp;Shin Yamada,&nbsp;Natsuo Konishi,&nbsp;Hitoshi Kubota,&nbsp;Hiroshi Tazawa,&nbsp;Takayuki Tani,&nbsp;Norio Suzuki,&nbsp;Keiji Kamo,&nbsp;Yoshihiko Okudera,&nbsp;Masashi Fujii,&nbsp;Ken Sasaki,&nbsp;Tetsuya Kawano,&nbsp;Yosuke Iwamoto,&nbsp;Itsuki Nagahata,&nbsp;Takanori Miura,&nbsp;Naohisa Miyakoshi,&nbsp;Yoichi Shimada","doi":"10.1177/1179544120946747","DOIUrl":"https://doi.org/10.1177/1179544120946747","url":null,"abstract":"<p><strong>Purpose: </strong>In osteoarthritis of the hip, the pain may be strong even if the deformity is mild, but the pain may be mild even if the deformity is severe. If the factors related to the pain can be identified on imaging, reducing such factors can alleviate the pain, and effective measures can be taken for cases where surgery cannot be performed. In addition, imaging findings related to the pain are also important information for determining the procedures and the timing of surgery. Thus, the purpose of this study was to identify the differences in features of osteoarthritis seen on imaging between painless and painful osteoarthritis of the hip.</p><p><strong>Methods: </strong>The subjects were the patients with hip osteoarthritis who visited our department in 2015 and who underwent x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), a total of 29 patients (54 hip joints; mean age 63 years; 8 males and 21 females). The degree of osteoarthritis was determined using the Tönnis grade from the x-ray image. The cartilage morphology, intensity changes of bone marrow on MRI (subchondral bone marrow lesions [BMLs]), osteophytes, joint effusions, and paralabral cysts were scored based on the Hip Osteoarthritis MRI Scoring System (HOAMS). The cross-sectional area of the psoas major muscle at the level of the iliac crest was measured on CT, and the psoas index (PI; the cross-sectional area ratio of the psoas major muscle to the lumbar 4/5 intervertebral disc) was calculated to correct for the difference in physique. Then, the relationships between these and visual analog scale (VAS) scores of pains were evaluated.</p><p><strong>Results: </strong>The average VAS was 55.4 ± 39 mm. The PI and all items of HOAMS correlated with the VAS. The average VAS of Tönnis grade 3 osteoarthritis was 75.8 ± 26 mm. When investigating only Tönnis grade 3 osteoarthritis, the differences between cases with less than average pain and those with above average pain were the BML score in the central-inferior femoral head (<i>P</i> = .0213), the osteophyte score of the inferomedial femoral head (<i>P</i> = .0325), and the PI (<i>P</i> = .0292).</p><p><strong>Conclusion: </strong>Investigation of the differences between painless and painful osteoarthritis of the hip showed that the cases with more pain have BMLs of the femoral head on MRI that extend not only to the loading area, but also to the central-inferior area. Even with the same x-ray findings, the pain was stronger in patients with severe psoas atrophy. Thus, the instability due to muscle atrophy may also play a role in the pain of hip osteoarthritis.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"13 ","pages":"1179544120946747"},"PeriodicalIF":2.6,"publicationDate":"2020-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179544120946747","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38283493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis. 患者报告的富血小板血浆、骨髓抽吸和脂肪来源间充质干细胞注射治疗症状性膝骨关节炎的结果
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2020-07-03 eCollection Date: 2020-01-01 DOI: 10.1177/1179544120931086
Esteban Estrada, Jose L Décima, Marcelo Rodríguez, Marianela Di Tomaso, Javier Roberti

Objective: The objective of this study was to compare platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived mesenchymal stem cell (MSC) injections in the treatment of osteoarthritis (OA) of the knee using functional scores.

Methods: A total of 89 patients with painful knee OA were included in this study. Patients were assigned to one of the 3 treatments according to severity of OA as indicated by symptoms and radiography to PRP (stage I), BMAC (stage II), or adipose-derived MSC (stage III). Clinical assessment was performed using the Knee Society Score, which combines the Knee Score, based on the clinical parameters, and the Functional Score, and IKDC score. Surveys were completed at preoperative and at 90, 180, and 265 days postoperative. The follow-up responses were compared with baseline and between treatment groups.

Results: Treatment with PRP, BMAC, and adipose-derived MSC included 29 (32.6%), 27 (30.3%), and 33 (37.1%) patients, respectively. For the total group, median age was 61 years (range: 22-84 years). Score values were comparable among treatment groups at baseline. Statistically significant improvement was observed in the 3 groups according to the 3 scores at all time points during follow-up compared with baseline. No difference was found among treatment type.

Conclusions: Our findings support previous reports and encourage further research on the use of these cost-effective treatments for OA of the knee.

目的:本研究的目的是通过功能评分比较富血小板血浆(PRP)、骨髓抽吸浓缩液(BMAC)和脂肪源性间充质干细胞(MSC)注射治疗膝关节骨关节炎(OA)的效果。方法:89例膝关节骨性关节炎患者为研究对象。根据症状和影像学显示的OA严重程度,将患者分配到PRP (I期)、BMAC (II期)或脂肪源性MSC (III期)的3种治疗方法之一。临床评估使用膝关节社会评分,该评分结合了基于临床参数的膝关节评分、功能评分和IKDC评分。调查分别于术前、术后90天、180天和265天完成。将随访反应与基线和治疗组之间进行比较。结果:PRP、BMAC和脂肪来源的MSC治疗分别包括29例(32.6%)、27例(30.3%)和33例(37.1%)患者。整个组中位年龄为61岁(范围:22-84岁)。各治疗组在基线时的评分值具有可比性。3组患者随访各时间点的3项评分均较基线有统计学意义的改善。不同处理类型间无差异。结论:我们的研究结果支持先前的报道,并鼓励进一步研究这些具有成本效益的治疗膝关节OA的方法。
{"title":"Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis.","authors":"Esteban Estrada,&nbsp;Jose L Décima,&nbsp;Marcelo Rodríguez,&nbsp;Marianela Di Tomaso,&nbsp;Javier Roberti","doi":"10.1177/1179544120931086","DOIUrl":"https://doi.org/10.1177/1179544120931086","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to compare platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived mesenchymal stem cell (MSC) injections in the treatment of osteoarthritis (OA) of the knee using functional scores.</p><p><strong>Methods: </strong>A total of 89 patients with painful knee OA were included in this study. Patients were assigned to one of the 3 treatments according to severity of OA as indicated by symptoms and radiography to PRP (stage I), BMAC (stage II), or adipose-derived MSC (stage III). Clinical assessment was performed using the Knee Society Score, which combines the Knee Score, based on the clinical parameters, and the Functional Score, and IKDC score. Surveys were completed at preoperative and at 90, 180, and 265 days postoperative. The follow-up responses were compared with baseline and between treatment groups.</p><p><strong>Results: </strong>Treatment with PRP, BMAC, and adipose-derived MSC included 29 (32.6%), 27 (30.3%), and 33 (37.1%) patients, respectively. For the total group, median age was 61 years (range: 22-84 years). Score values were comparable among treatment groups at baseline. Statistically significant improvement was observed in the 3 groups according to the 3 scores at all time points during follow-up compared with baseline. No difference was found among treatment type.</p><p><strong>Conclusions: </strong>Our findings support previous reports and encourage further research on the use of these cost-effective treatments for OA of the knee.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"13 ","pages":"1179544120931086"},"PeriodicalIF":2.6,"publicationDate":"2020-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179544120931086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38156432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Atlantoaxial Rotatory Subluxation in a 10-Year-Old Boy. 10岁男孩寰枢椎旋转半脱位1例。
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2020-07-01 eCollection Date: 2020-01-01 DOI: 10.1177/1179544120939069
Eric Chun Pu Chu, Divya Midhun Chakkaravarthy, Fa Sain Lo, Amiya Bhaumik

Atlantoaxial rotatory subluxation (AARS) is the loss of normal alignment and stability of the first (atlas) and second (axis) cervical vertebrae with respect to each other. We describe the clinical challenges of managing a 10-year-old boy who presented with repetitive episodes of torticollis. Open-mouth odontoid radiograph and computed tomographic (CT) scan gave a diagnosis in ARRS, based on its characteristic imaging findings. The child was admitted multiple times for continuous halter traction in the first 6 months after symptom onset. He also experienced a temporary complication from an overcorrection with correcting neck bracing. Seven months after symptom onset, this case was discussed by a multidisciplinary spine team and referred to chiropractic clinic. Despite persistent radiographic evidence of atlantoaxial instability, after 5 months of chiropractic treatment, the child was asymptomatic with nearly full range of neck movement. He also weaned off acetaminophen he had been taking over the past year. Incidentally, bilateral gynecomastia was discovered at the surveillance after treatment. The incidental finding of innocent gynecomastia, even if common in preteen boys, brings up the topic of acetaminophen's effects on the regulation of sex hormones that was previously overlooked.

寰枢旋转半脱位(AARS)是指第一(寰椎)和第二(颈椎)相对于彼此的正常对齐和稳定性的丧失。我们描述的临床挑战管理一个10岁的男孩谁提出了反复发作的斜颈。根据其特征性影像学表现,张嘴齿状突x线片和计算机断层扫描(CT)诊断为ARRS。患儿在症状出现后的前6个月多次入院接受持续笼头牵引。他还经历了颈部矫正支架矫治过度的暂时并发症。症状出现七个月后,本病例由多学科脊柱小组讨论,并转介到捏脊诊所。尽管有持续的寰枢椎不稳的x线证据,但经过5个月的整脊治疗后,儿童无症状,颈部活动范围几乎全。他还戒掉了去年服用的对乙酰氨基酚。顺便说一句,在治疗后的监测中发现了双侧男性乳房。偶然发现的无辜的男性乳房发育症,即使在青春期前的男孩中很常见,也引发了对乙酰氨基酚对性激素调节的影响这一话题,这一话题以前被忽视了。
{"title":"Atlantoaxial Rotatory Subluxation in a 10-Year-Old Boy.","authors":"Eric Chun Pu Chu,&nbsp;Divya Midhun Chakkaravarthy,&nbsp;Fa Sain Lo,&nbsp;Amiya Bhaumik","doi":"10.1177/1179544120939069","DOIUrl":"https://doi.org/10.1177/1179544120939069","url":null,"abstract":"<p><p>Atlantoaxial rotatory subluxation (AARS) is the loss of normal alignment and stability of the first (atlas) and second (axis) cervical vertebrae with respect to each other. We describe the clinical challenges of managing a 10-year-old boy who presented with repetitive episodes of torticollis. Open-mouth odontoid radiograph and computed tomographic (CT) scan gave a diagnosis in ARRS, based on its characteristic imaging findings. The child was admitted multiple times for continuous halter traction in the first 6 months after symptom onset. He also experienced a temporary complication from an overcorrection with correcting neck bracing. Seven months after symptom onset, this case was discussed by a multidisciplinary spine team and referred to chiropractic clinic. Despite persistent radiographic evidence of atlantoaxial instability, after 5 months of chiropractic treatment, the child was asymptomatic with nearly full range of neck movement. He also weaned off acetaminophen he had been taking over the past year. Incidentally, bilateral gynecomastia was discovered at the surveillance after treatment. The incidental finding of innocent gynecomastia, even if common in preteen boys, brings up the topic of acetaminophen's effects on the regulation of sex hormones that was previously overlooked.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"13 ","pages":"1179544120939069"},"PeriodicalIF":2.6,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179544120939069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38150708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Shoulder Double Crush Syndrome: A Retrospective Study of Patients With Concomitant Suprascapular Neuropathy and Cervical Radiculopathy. 肩双压伤综合征:肩胛上神经病变合并颈神经根病患者的回顾性研究。
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2020-06-22 eCollection Date: 2020-01-01 DOI: 10.1177/1179544120921854
Yoshihiro Katsuura, Katherine Yao, Eric Chang, Tareck A Kadrie, John A Dorizas

Purpose: While the double crush phenomena (compression along two points on a nerve) has been established between median neuropathy and cervical radiculopathy, combined suprascapular neuropathy (SSN) and cervical C5/C6 radiculopathy-so-called shoulder double crush syndrome-has not been well examined. We aim to identify the incidence of shoulder double crush syndrome in patients undergoing arthroscopic suprascapular nerve release for SSN.

Methods: One hundred consecutive patients >18 years of age who were positive for SSN on electromyography and motor nerve conduction studies (EMG/NCS) and underwent a suprascapular nerve release were included. Patients with evidence of shoulder double crush syndrome were identified based on x ray, cervical spine magnetic resonance imaging (MRI) and examination findings. Demographics, electrodiagnostics results, treatment courses, and clinical outcomes (visual analog scores and rotator cuff strength) following arthroscopic suprascapular nerve release were compared between patients with double crush syndrome versus isolated SSN.

Results: Thirty one percent of patients had evidence of shoulder crush syndrome. Two significant electrophysiologic differences were noted in shoulder double crush patients compared to isolated SSN patients. Patients with double crush had an increased incidence of median neuropathy (51% vs 30%, P = .04). Double crush patients had less supraspinatus motor amplitude difference between the affected side and non-affected side compared to isolated SSN patients (2.62 mV vs 3.44 mV, P = .03). In general, most double crush patients were treated conservatively with regard to their cervical spine pathology.

Conclusion: A significant percentage of patients with SSN have evidence of shoulder double crush syndrome. Patients with SSN and concomitant median neuropathy should have a detailed neck examination performed.

目的:虽然在正中神经病变和颈神经根病之间存在双重挤压现象(沿神经两点受压),但肩胛上神经病变(SSN)和颈C5/C6神经根病合并-即所谓的肩部双重挤压综合征-尚未得到很好的研究。我们的目的是确定肩胛上神经松解术患者肩关节双重挤压综合征的发生率。方法:连续100例年龄>18岁,肌电图和运动神经传导(EMG/NCS)阳性,并行肩胛上神经释放术的患者。根据x线,颈椎磁共振成像(MRI)和检查结果确定有肩部双挤压综合征证据的患者。比较了双重挤压综合征患者与孤立性SSN患者在关节镜下肩胛上神经释放后的人口统计学、电诊断结果、疗程和临床结果(视觉模拟评分和肩袖强度)。结果:31%的患者有肩压综合征的证据。与孤立的SSN患者相比,双肩关节挤压患者有两个显著的电生理差异。双挤压患者中位神经病变发生率增加(51% vs 30%, P = 0.04)。与孤立的SSN患者相比,双挤压患者患侧和非患侧冈上肌运动振幅差异较小(2.62 mV vs 3.44 mV, P = 0.03)。一般来说,大多数双重挤压患者在颈椎病理方面采用保守治疗。结论:相当比例的SSN患者有肩部双挤压综合征的证据。伴有SSN并伴有正中神经病变的患者应进行详细的颈部检查。
{"title":"Shoulder Double Crush Syndrome: A Retrospective Study of Patients With Concomitant Suprascapular Neuropathy and Cervical Radiculopathy.","authors":"Yoshihiro Katsuura,&nbsp;Katherine Yao,&nbsp;Eric Chang,&nbsp;Tareck A Kadrie,&nbsp;John A Dorizas","doi":"10.1177/1179544120921854","DOIUrl":"https://doi.org/10.1177/1179544120921854","url":null,"abstract":"<p><strong>Purpose: </strong>While the double crush phenomena (compression along two points on a nerve) has been established between median neuropathy and cervical radiculopathy, combined suprascapular neuropathy (SSN) and cervical C5/C6 radiculopathy-so-called shoulder double crush syndrome-has not been well examined. We aim to identify the incidence of shoulder double crush syndrome in patients undergoing arthroscopic suprascapular nerve release for SSN.</p><p><strong>Methods: </strong>One hundred consecutive patients >18 years of age who were positive for SSN on electromyography and motor nerve conduction studies (EMG/NCS) and underwent a suprascapular nerve release were included. Patients with evidence of shoulder double crush syndrome were identified based on x ray, cervical spine magnetic resonance imaging (MRI) and examination findings. Demographics, electrodiagnostics results, treatment courses, and clinical outcomes (visual analog scores and rotator cuff strength) following arthroscopic suprascapular nerve release were compared between patients with double crush syndrome versus isolated SSN.</p><p><strong>Results: </strong>Thirty one percent of patients had evidence of shoulder crush syndrome. Two significant electrophysiologic differences were noted in shoulder double crush patients compared to isolated SSN patients. Patients with double crush had an increased incidence of median neuropathy (51% vs 30%, <i>P</i> = .04). Double crush patients had less supraspinatus motor amplitude difference between the affected side and non-affected side compared to isolated SSN patients (2.62 mV vs 3.44 mV, <i>P</i> = .03). In general, most double crush patients were treated conservatively with regard to their cervical spine pathology.</p><p><strong>Conclusion: </strong>A significant percentage of patients with SSN have evidence of shoulder double crush syndrome. Patients with SSN and concomitant median neuropathy should have a detailed neck examination performed.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"13 ","pages":"1179544120921854"},"PeriodicalIF":2.6,"publicationDate":"2020-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179544120921854","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38110180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Midfoot Arthritis in Children: Is There Any Relation With Malignancy? 儿童中足关节炎:是否与恶性肿瘤有关?
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2020-06-08 eCollection Date: 2020-01-01 DOI: 10.1177/1179544120924643
Reza Shiari, Nargess Salar, Vadood Javadi Parvneh, Khosro Rahmani, Mehrnoush Hassas Yeganeh, Sara Shiari

Background: Musculoskeletal symptoms are a presenting manifestation in a number of lymphoproliferative disorders including leukemia, especially in children. Among these primary symptoms, midfoot arthritis seems to be an important alarm for malignancy in children. The aim of this study is evaluation association of midfoot arthritis with malignancy in children.

Method: In this cross-sectional study, all medical records of patients with arthritis were identified and reviewed. All clinical and laboratory data were recorded in the information form and data were analyzed by SPSS 25 software.

Results: A total of 557 cases of arthritis were evaluated, of which 18 (3.2%) cases have primary symptoms of midfoot arthritis. Four of 18 patients (22.2%) had B-cell precursor acute lymphoblastic leukemia, that midfoot arthritis was their first manifestation. Also, their laboratory findings confirmed that platelet, lactic acid dehydrogenesis, and uric acid values were significantly higher in these children. Based on statistical evaluation, there was no significant difference between age and sex in these patients.

Conclusion: According to the findings of the present study, it can be concluded that "midfoot arthritis" may be the first manifestation of leukemia in children even with a near-normal hematologic values.

背景:肌肉骨骼症状是包括白血病在内的许多淋巴增生性疾病的主要表现,尤其是在儿童中。在这些主要症状中,足中关节炎似乎是儿童恶性肿瘤的重要警报。本研究的目的是评估儿童中足关节炎与恶性肿瘤的关系。方法:在本横断面研究中,对所有关节炎患者的医疗记录进行识别和回顾。所有临床及实验室资料均以信息表记录,数据采用SPSS 25软件分析。结果:共评估557例关节炎,其中18例(3.2%)以足中关节炎为首发症状。18例患者中有4例(22.2%)为b细胞前体急性淋巴细胞白血病,首发表现为足中关节炎。此外,他们的实验室研究结果证实,这些儿童的血小板、乳酸脱氢和尿酸值明显较高。经统计学评价,患者的年龄、性别差异无统计学意义。结论:根据本研究结果,即使血液学值接近正常,“足中关节炎”也可能是儿童白血病的第一表现。
{"title":"Midfoot Arthritis in Children: Is There Any Relation With Malignancy?","authors":"Reza Shiari,&nbsp;Nargess Salar,&nbsp;Vadood Javadi Parvneh,&nbsp;Khosro Rahmani,&nbsp;Mehrnoush Hassas Yeganeh,&nbsp;Sara Shiari","doi":"10.1177/1179544120924643","DOIUrl":"https://doi.org/10.1177/1179544120924643","url":null,"abstract":"<p><strong>Background: </strong>Musculoskeletal symptoms are a presenting manifestation in a number of lymphoproliferative disorders including leukemia, especially in children. Among these primary symptoms, midfoot arthritis seems to be an important alarm for malignancy in children. The aim of this study is evaluation association of midfoot arthritis with malignancy in children.</p><p><strong>Method: </strong>In this cross-sectional study, all medical records of patients with arthritis were identified and reviewed. All clinical and laboratory data were recorded in the information form and data were analyzed by SPSS 25 software.</p><p><strong>Results: </strong>A total of 557 cases of arthritis were evaluated, of which 18 (3.2%) cases have primary symptoms of midfoot arthritis. Four of 18 patients (22.2%) had B-cell precursor acute lymphoblastic leukemia, that midfoot arthritis was their first manifestation. Also, their laboratory findings confirmed that platelet, lactic acid dehydrogenesis, and uric acid values were significantly higher in these children. Based on statistical evaluation, there was no significant difference between age and sex in these patients.</p><p><strong>Conclusion: </strong>According to the findings of the present study, it can be concluded that \"midfoot arthritis\" may be the first manifestation of leukemia in children even with a near-normal hematologic values.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"13 ","pages":"1179544120924643"},"PeriodicalIF":2.6,"publicationDate":"2020-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179544120924643","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38060131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis. 大麻素在慢性非癌性疼痛中的作用:系统综述和荟萃分析。
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2020-02-19 eCollection Date: 2020-01-01 DOI: 10.1177/1179544120906461
Herman Johal, Tahira Devji, Yaping Chang, Jonathan Simone, Christopher Vannabouathong, Mohit Bhandari
<p><strong>Background: </strong>For patients with chronic, non-cancer pain, traditional pain-relieving medications include opioids, which have shown benefits but are associated with increased risks of addiction and adverse effects. Medical cannabis has emerged as a treatment alternative for managing these patients and there has been a rise in the number of randomized clinical trials in recent years; therefore, a systematic review of the evidence was warranted.</p><p><strong>Objective: </strong>To analyze the evidence surrounding the benefits and harms of medical cannabinoids in the treatment of chronic, non-cancer-related pain.</p><p><strong>Design: </strong>Systematic review with meta-analysis.</p><p><strong>Data sources: </strong>Medline, Embase, CINAHL, SCOPUS, Google Scholar, and Cochrane Databases.</p><p><strong>Eligibility criteria: </strong>English language randomized clinical trials of cannabinoids for the treatment of chronic, non-cancer-related pain.</p><p><strong>Data extraction and synthesis: </strong>Study quality was assessed using the Cochrane risk of bias tool. All stages were conducted independently by a team of 6 reviewers. Data were pooled through meta-analysis with different durations of treatment (2 weeks, 2 months, 6 months) and stratified by route of administration (smoked, oromucosal, oral), conditions, and type of cannabinoids.</p><p><strong>Main outcomes and measures: </strong>Patient-reported pain and adverse events (AEs).</p><p><strong>Results: </strong>Thirty-six trials (4006 participants) were included, examining smoked cannabis (4 trials), oromucosal cannabis sprays (14 trials), and oral cannabinoids (18 trials). Compared with placebo, cannabinoids showed a significant reduction in pain which was greatest with treatment duration of 2 to 8 weeks (weighted mean difference on a 0-10 pain visual analogue scale -0.68, 95% confidence interval [CI], -0.96 to -0.40, <i>I</i> <sup>2</sup> = 8%, <i>P</i> < .00001; n = 16 trials). When stratified by route of administration, pain condition, and type of cannabinoids, oral cannabinoids had a larger reduction in pain compared with placebo relative to oromucosal and smoked formulations but the difference was not significant (<i>P</i>[interaction] > .05 in all the 3 durations of treatment); cannabinoids had a smaller reduction in pain due to multiple sclerosis compared with placebo relative to other neuropathic pain (<i>P</i>[interaction] = .05) within 2 weeks and the difference was not significant relative to pain due to rheumatic arthritis; nabilone had a greater reduction in pain compared with placebo relative to other types of cannabinoids longer than 2 weeks of treatment but the difference was not significant (<i>P</i>[interaction] > .05). Serious AEs were rare, and similar across the cannabinoid (74 out of 2176, 3.4%) and placebo groups (53 out of 1640, 3.2%). There was an increased risk of non-serious AEs with cannabinoids compared with placebo.</p><p><strong>Conclusions: </s
背景:对于慢性、非癌性疼痛患者,传统的止痛药物包括阿片类药物,它已显示出益处,但与成瘾和不良反应的风险增加有关。医用大麻已成为管理这些患者的一种替代治疗方法,近年来,随机临床试验的数量有所增加;因此,有必要对证据进行系统审查。目的:分析医用大麻素治疗慢性非癌相关性疼痛的利与弊的相关证据。设计:采用荟萃分析的系统评价。数据来源:Medline, Embase, CINAHL, SCOPUS, Google Scholar和Cochrane数据库。入选标准:大麻素治疗慢性非癌症相关疼痛的英语随机临床试验。数据提取和综合:使用Cochrane偏倚风险工具评估研究质量。所有阶段均由6名评审员组成的团队独立进行。通过荟萃分析收集不同治疗持续时间(2周、2个月、6个月)的数据,并根据给药途径(烟熏、口黏膜、口服)、病情和大麻素类型进行分层。主要结局和测量:患者报告的疼痛和不良事件(ae)。结果:纳入36项试验(4006名受试者),研究了吸烟大麻(4项试验)、口腔黏膜大麻喷雾剂(14项试验)和口服大麻素(18项试验)。与安慰剂相比,大麻素显著减轻疼痛,治疗时间为2至8周时效果最显著(0-10疼痛视觉模拟量表加权平均差为-0.68,95%可信区间[CI], -0.96至-0.40,i2 = 8%, P P[相互作用]>)。3个疗程均为0.05);与安慰剂相比,大麻素在2周内对多发性硬化症引起的疼痛的减轻幅度较小,相对于其他神经性疼痛(P[相互作用]= 0.05),相对于风湿性关节炎引起的疼痛,差异不显著;纳比龙在治疗2周以上的时间内,与安慰剂相比,与其他类型的大麻素相比,纳比龙更能减轻疼痛,但差异不显著(P[相互作用]> 0.05)。严重不良事件很少见,大麻素组(2176人中有74人,3.4%)和安慰剂组(1640人中有53人,3.2%)相似。与安慰剂相比,大麻素增加了非严重不良反应的风险。结论:有中度证据支持大麻素治疗慢性非癌性疼痛2周。在后来的时间点观察到类似的结果,但对效果的置信度很低。几乎没有证据表明大麻素会增加经历严重不良反应的风险,尽管在使用后的短期内非严重不良反应可能很常见。
{"title":"Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis.","authors":"Herman Johal,&nbsp;Tahira Devji,&nbsp;Yaping Chang,&nbsp;Jonathan Simone,&nbsp;Christopher Vannabouathong,&nbsp;Mohit Bhandari","doi":"10.1177/1179544120906461","DOIUrl":"https://doi.org/10.1177/1179544120906461","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;For patients with chronic, non-cancer pain, traditional pain-relieving medications include opioids, which have shown benefits but are associated with increased risks of addiction and adverse effects. Medical cannabis has emerged as a treatment alternative for managing these patients and there has been a rise in the number of randomized clinical trials in recent years; therefore, a systematic review of the evidence was warranted.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To analyze the evidence surrounding the benefits and harms of medical cannabinoids in the treatment of chronic, non-cancer-related pain.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Systematic review with meta-analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data sources: &lt;/strong&gt;Medline, Embase, CINAHL, SCOPUS, Google Scholar, and Cochrane Databases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Eligibility criteria: &lt;/strong&gt;English language randomized clinical trials of cannabinoids for the treatment of chronic, non-cancer-related pain.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data extraction and synthesis: &lt;/strong&gt;Study quality was assessed using the Cochrane risk of bias tool. All stages were conducted independently by a team of 6 reviewers. Data were pooled through meta-analysis with different durations of treatment (2 weeks, 2 months, 6 months) and stratified by route of administration (smoked, oromucosal, oral), conditions, and type of cannabinoids.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Patient-reported pain and adverse events (AEs).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Thirty-six trials (4006 participants) were included, examining smoked cannabis (4 trials), oromucosal cannabis sprays (14 trials), and oral cannabinoids (18 trials). Compared with placebo, cannabinoids showed a significant reduction in pain which was greatest with treatment duration of 2 to 8 weeks (weighted mean difference on a 0-10 pain visual analogue scale -0.68, 95% confidence interval [CI], -0.96 to -0.40, &lt;i&gt;I&lt;/i&gt; &lt;sup&gt;2&lt;/sup&gt; = 8%, &lt;i&gt;P&lt;/i&gt; &lt; .00001; n = 16 trials). When stratified by route of administration, pain condition, and type of cannabinoids, oral cannabinoids had a larger reduction in pain compared with placebo relative to oromucosal and smoked formulations but the difference was not significant (&lt;i&gt;P&lt;/i&gt;[interaction] &gt; .05 in all the 3 durations of treatment); cannabinoids had a smaller reduction in pain due to multiple sclerosis compared with placebo relative to other neuropathic pain (&lt;i&gt;P&lt;/i&gt;[interaction] = .05) within 2 weeks and the difference was not significant relative to pain due to rheumatic arthritis; nabilone had a greater reduction in pain compared with placebo relative to other types of cannabinoids longer than 2 weeks of treatment but the difference was not significant (&lt;i&gt;P&lt;/i&gt;[interaction] &gt; .05). Serious AEs were rare, and similar across the cannabinoid (74 out of 2176, 3.4%) and placebo groups (53 out of 1640, 3.2%). There was an increased risk of non-serious AEs with cannabinoids compared with placebo.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/s","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"13 ","pages":"1179544120906461"},"PeriodicalIF":2.6,"publicationDate":"2020-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179544120906461","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37702214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 66
Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality. 服用阿那白拉治疗急性痛风的患者,其高尿酸血症、痛风、合并症和最终全因死亡率的基线负担增加。
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2019-12-09 eCollection Date: 2019-01-01 DOI: 10.1177/1179544119890853
Ena Sharma, Brian Pedersen, Robert Terkeltaub

Objective: The interleukin-1 (IL-1) receptor antagonist anakinra is an effective, off-label option in acute gout flares, when conventional therapy options are narrowed. We performed a retrospective, randomized, case-controlled study to gain clinical insight on baseline factors for gout patients most likely to receive anakinra, and ultimate mortality of those who received anakinra.

Methods: Of 1451 gout patients seen between January 2003 and January 2015 in a Veterans Affairs (VA) rheumatology group practice, under stringent managed care principles, 13 (100% male), who received anakinra at least once for flares, were compared with 1:4 age- and sex-matched gout controls. Each patient's first rheumatology encounter was studied by factor analysis for variables associated with later anakinra.

Results: At baseline, patients that received anakinra had higher urate burden (palpable tophi [10/13] vs controls [16/52], P = .003), serum urate ([10.6 mg/dL] vs controls [7.6 mg/dL], P < .0001), and East Asian descent ([7/13] vs [16/52], P = .041). The anakinra group had higher ultimate all-cause mortality ([6/13] vs controls [7/52], relative risk [RR] = 3.43, 95% confidence interval [CI] = 1.39-8.48, P = .0076). Factor analysis showed baseline visit palpable tophus and statin use to be most strongly associated with later anakinra use. Increased mortality of anakinra users, as per a factorial analysis, was linked more strongly to comorbidities than to anakinra.

Conclusions: At baseline rheumatology gout encounter, higher urate, palpable tophi, statin prescription, and East Asian descent were associated with later anakinra use for flares. Mortality was more closely associated to the presence of comorbidities at baseline rheumatology visit than to anakinra prescription.

目的:白细胞介素-1 (IL-1)受体拮抗剂anakinra是治疗急性痛风发作的一种有效的非适应症治疗方案,当常规治疗方案缩小时。我们进行了一项回顾性、随机、病例对照研究,以获得最有可能接受阿那白的痛风患者的基线因素和接受阿那白患者的最终死亡率的临床见解。方法:在2003年1月至2015年1月期间,在退伍军人事务部(VA)风湿病组实践中,在严格的管理护理原则下,1451例痛风患者中,13例(100%男性)接受了阿那白至少一次的耀发,与1:4年龄和性别匹配的痛风对照组进行比较。每个患者的第一次风湿病就诊都通过因子分析来研究与后来anakinra相关的变量。结果:在基线时,接受阿那白拉治疗的患者有更高的尿酸负荷(可触及的尿酸[10/13]比对照组[16/52],P = 0.003),血清尿酸([10.6 mg/dL]比对照组[7.6 mg/dL], P = 0.041)。阿那金组最终全因死亡率较高([6/13]vs对照组[7/52],相对危险度[RR] = 3.43, 95%可信区间[CI] = 1.39 ~ 8.48, P = 0.0076)。因子分析显示,基线访视可触及的痛风和他汀类药物的使用与后来的阿那白拉使用最密切相关。根据析因分析,阿那白拉使用者死亡率的增加与合并症的关系比与阿那白拉的关系更强。结论:在基线风湿病痛风遭遇时,较高的尿酸、可触及的痛风石、他汀类药物处方和东亚血统与后来使用阿那白来治疗耀斑有关。在基线风湿病就诊时,死亡率与合并症的存在密切相关,而与阿那金的处方无关。
{"title":"Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality.","authors":"Ena Sharma,&nbsp;Brian Pedersen,&nbsp;Robert Terkeltaub","doi":"10.1177/1179544119890853","DOIUrl":"https://doi.org/10.1177/1179544119890853","url":null,"abstract":"<p><strong>Objective: </strong>The interleukin-1 (IL-1) receptor antagonist anakinra is an effective, off-label option in acute gout flares, when conventional therapy options are narrowed. We performed a retrospective, randomized, case-controlled study to gain clinical insight on baseline factors for gout patients most likely to receive anakinra, and ultimate mortality of those who received anakinra.</p><p><strong>Methods: </strong>Of 1451 gout patients seen between January 2003 and January 2015 in a Veterans Affairs (VA) rheumatology group practice, under stringent managed care principles, 13 (100% male), who received anakinra at least once for flares, were compared with 1:4 age- and sex-matched gout controls. Each patient's first rheumatology encounter was studied by factor analysis for variables associated with later anakinra.</p><p><strong>Results: </strong>At baseline, patients that received anakinra had higher urate burden (palpable tophi [10/13] vs controls [16/52], <i>P</i> = .003), serum urate ([10.6 mg/dL] vs controls [7.6 mg/dL], <i>P</i> < .0001), and East Asian descent ([7/13] vs [16/52], <i>P</i> = .041). The anakinra group had higher ultimate all-cause mortality ([6/13] vs controls [7/52], relative risk [RR] = 3.43, 95% confidence interval [CI] = 1.39-8.48, <i>P</i> = .0076). Factor analysis showed baseline visit palpable tophus and statin use to be most strongly associated with later anakinra use. Increased mortality of anakinra users, as per a factorial analysis, was linked more strongly to comorbidities than to anakinra.</p><p><strong>Conclusions: </strong>At baseline rheumatology gout encounter, higher urate, palpable tophi, statin prescription, and East Asian descent were associated with later anakinra use for flares. Mortality was more closely associated to the presence of comorbidities at baseline rheumatology visit than to anakinra prescription.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"12 ","pages":"1179544119890853"},"PeriodicalIF":2.6,"publicationDate":"2019-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179544119890853","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37459564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Safety of Intra-articular Methotrexate Injection With and Without Electroporation for Inflammatory Small Joints in Patients With Rheumatoid Arthritis 类风湿性关节炎患者炎性小关节内注射甲氨蝶呤有无电穿孔的安全性
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2019-11-01 DOI: 10.1177/1179544119886303
M. Tada, K. Inui, T. Okano, K. Mamoto, T. Koike, Hiroaki Nakamura
The general disease activity of patients with rheumatoid arthritis (RA) is well controlled by disease-modifying antirheumatic drugs, but local inflammation often remains in a few small joints. Electroporation, making small pores in cell membranes, has proven useful for drug delivery. The safety of a combination therapy of methotrexate (MTX) and electroporation for local joint inflammation in RA was investigated in a prospective, randomized, double-blind, placebo-controlled, exploratory study (UMIN000016606). The patients were randomly allocated to groups receiving a combination of MTX and electroporation (True-EP) and MTX alone (False-EP) groups. The MTX solution was injected into finger joints under ultrasound guidance. The True-EP group underwent electroporation with MTX, and the False-EP group was given MTX but only pinched using the electrode. The ultrasound grade, disease activity, and safety were evaluated from baseline to 26 weeks. Five patients (3 True-EP and 2 False-EP) with a mean age of 57.4 years and disease duration of 10.2 years were enrolled. The grey-scale grade was unchanged in 3 cases (2 True-EP and 1 False-EP) and increased in 2 cases (1 True-EP and 1 False-EP). Disease activity was alleviated in 3 cases (2 True-EP and 1 False-EP). No patients experienced burned skin or electroshock. The combination therapy of electroporation and MTX was safe for RA patients.
类风湿关节炎(RA)患者的一般疾病活动度可以通过改善疾病的抗风湿药物得到很好的控制,但局部炎症往往停留在少数小关节。电穿孔,在细胞膜上形成小孔,已被证明对药物输送有用。在一项前瞻性、随机、双盲、安慰剂对照的探索性研究(UMIN000016606)中,研究了甲氨蝶呤(MTX)和电穿孔联合治疗类风湿关节炎局部关节炎症的安全性。患者被随机分为MTX联合电穿孔组(True-EP)和单独MTX组(False-EP)。在超声引导下将MTX溶液注入手指关节。True-EP组用MTX进行电穿孔,False-EP组给予MTX,但只使用电极夹紧。从基线到26周,对超声分级、疾病活动性和安全性进行评估。5例患者(3例真ep和2例假ep),平均年龄57.4岁,病程10.2年。3例(2例True-EP和1例False-EP)灰度等级不变,2例(1例True-EP和1例False-EP)灰度等级升高。3例(2例真ep, 1例假ep)疾病活动度减轻。没有患者出现皮肤烧伤或电击。电穿孔联合甲氨蝶呤治疗RA是安全的。
{"title":"Safety of Intra-articular Methotrexate Injection With and Without Electroporation for Inflammatory Small Joints in Patients With Rheumatoid Arthritis","authors":"M. Tada, K. Inui, T. Okano, K. Mamoto, T. Koike, Hiroaki Nakamura","doi":"10.1177/1179544119886303","DOIUrl":"https://doi.org/10.1177/1179544119886303","url":null,"abstract":"The general disease activity of patients with rheumatoid arthritis (RA) is well controlled by disease-modifying antirheumatic drugs, but local inflammation often remains in a few small joints. Electroporation, making small pores in cell membranes, has proven useful for drug delivery. The safety of a combination therapy of methotrexate (MTX) and electroporation for local joint inflammation in RA was investigated in a prospective, randomized, double-blind, placebo-controlled, exploratory study (UMIN000016606). The patients were randomly allocated to groups receiving a combination of MTX and electroporation (True-EP) and MTX alone (False-EP) groups. The MTX solution was injected into finger joints under ultrasound guidance. The True-EP group underwent electroporation with MTX, and the False-EP group was given MTX but only pinched using the electrode. The ultrasound grade, disease activity, and safety were evaluated from baseline to 26 weeks. Five patients (3 True-EP and 2 False-EP) with a mean age of 57.4 years and disease duration of 10.2 years were enrolled. The grey-scale grade was unchanged in 3 cases (2 True-EP and 1 False-EP) and increased in 2 cases (1 True-EP and 1 False-EP). Disease activity was alleviated in 3 cases (2 True-EP and 1 False-EP). No patients experienced burned skin or electroshock. The combination therapy of electroporation and MTX was safe for RA patients.","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"21 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74860227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Reliability and Accuracy of MRI in Orthopedics: A Survey of Its Use and Perceived Limitations. MRI在骨科的可靠性和准确性:对其使用和感知局限性的调查。
IF 2.6 Q2 ORTHOPEDICS Pub Date : 2019-09-05 eCollection Date: 2019-01-01 DOI: 10.1177/1179544119872972
Andrew Hong, Joseph N Liu, Anirudh K Gowd, Aman Dhawan, Nirav H Amin

Over the past decade, the use of magnetic resonance imaging (MRI) as a diagnostic tool has been increasing significantly in various fields of medicine due to its wide array of applications. As a result, its diagnostic efficacy and reliability come into question. Specifically, in the field of orthopedics, there has been little discussion on the problems many physicians face while using MRIs in practice. To gauge the perceived limitations of MRI, we designed a decision analysis to analyze the utility of MRIs and estimate the number of inconclusive MRIs ordered within an orthopedic practice to explore potential alternative avenues of diagnosis. A survey of 100 board-certified practicing orthopedic surgeons given at 2 national conferences was designed to assess the value, reliability, and diagnostic utility of MRIs in preoperative planning in shoulder and knee surgery. Of those surveyed, 93% reported that there was believed to be a problem with the accuracy of an MRI in the setting of a prior surgery and/or if previous hardware was present specifically pertaining to the knee or shoulder. The most common indications of concern regarding knee or shoulder MRI reliability among this sample group were previous patient hardware (19%), a previous surgery (16%), and a chondral defect (11%). In addition, when asked how many MRIs were believed to be inconclusive based on previous surgery/hardware alone in the last 6 months of practice, an average of 19 inconclusive MRIs was reported. This study summarizes some of the concerns of MRI use in the orthopedic community and attempts to add a unique perspective on the attitudes, decision-making, and apparent economic problems that they face as well as uncover specific instances where MRIs were determined to be unreliable and incomplete in aiding the diagnosis and treatment algorithm.

在过去的十年里,磁共振成像(MRI)作为一种诊断工具,由于其广泛的应用,在医学的各个领域中的使用都在显著增加。因此,它的诊断功效和可靠性受到质疑。具体来说,在骨科领域,很少有人讨论许多医生在实践中使用核磁共振成像时面临的问题。为了衡量MRI的感知局限性,我们设计了一个决策分析来分析MRI的效用,并估计骨科手术中不确定的MRI数量,以探索潜在的替代诊断途径。在两次全国会议上,对100名委员会认证的执业骨科医生进行了一项调查,旨在评估MRI在肩膝手术术前计划中的价值、可靠性和诊断实用性。在接受调查的人中,93%的人报告说,在之前的手术和/或之前是否存在专门与膝盖或肩膀有关的硬件时,MRI的准确性被认为存在问题。在该样本组中,最常见的膝关节或肩部MRI可靠性指标是既往患者硬件(19%)、既往手术(16%)和软骨缺损(11%)。此外,当被问及在过去6年中,仅根据以前的手术/硬件,有多少核磁共振成像被认为是不确定的 经过数月的实践,平均报告了19例不确定的核磁共振成像。这项研究总结了骨科社区对MRI使用的一些担忧,并试图对他们面临的态度、决策和明显的经济问题添加一个独特的视角,并揭示MRI在辅助诊断和治疗算法方面被确定为不可靠和不完整的具体情况。
{"title":"Reliability and Accuracy of MRI in Orthopedics: A Survey of Its Use and Perceived Limitations.","authors":"Andrew Hong,&nbsp;Joseph N Liu,&nbsp;Anirudh K Gowd,&nbsp;Aman Dhawan,&nbsp;Nirav H Amin","doi":"10.1177/1179544119872972","DOIUrl":"https://doi.org/10.1177/1179544119872972","url":null,"abstract":"<p><p>Over the past decade, the use of magnetic resonance imaging (MRI) as a diagnostic tool has been increasing significantly in various fields of medicine due to its wide array of applications. As a result, its diagnostic efficacy and reliability come into question. Specifically, in the field of orthopedics, there has been little discussion on the problems many physicians face while using MRIs in practice. To gauge the perceived limitations of MRI, we designed a decision analysis to analyze the utility of MRIs and estimate the number of inconclusive MRIs ordered within an orthopedic practice to explore potential alternative avenues of diagnosis. A survey of 100 board-certified practicing orthopedic surgeons given at 2 national conferences was designed to assess the value, reliability, and diagnostic utility of MRIs in preoperative planning in shoulder and knee surgery. Of those surveyed, 93% reported that there was believed to be a problem with the accuracy of an MRI in the setting of a prior surgery and/or if previous hardware was present specifically pertaining to the knee or shoulder. The most common indications of concern regarding knee or shoulder MRI reliability among this sample group were previous patient hardware (19%), a previous surgery (16%), and a chondral defect (11%). In addition, when asked how many MRIs were believed to be inconclusive based on previous surgery/hardware alone in the last 6 months of practice, an average of 19 inconclusive MRIs was reported. This study summarizes some of the concerns of MRI use in the orthopedic community and attempts to add a unique perspective on the attitudes, decision-making, and apparent economic problems that they face as well as uncover specific instances where MRIs were determined to be unreliable and incomplete in aiding the diagnosis and treatment algorithm.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"12 ","pages":"1179544119872972"},"PeriodicalIF":2.6,"publicationDate":"2019-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179544119872972","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41193595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
期刊
Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1